


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-31 (Canceled)

Claim 32 (Currently Amended) A The method of claim 31 of treating leukemia comprising administering to a human patient in need of such treatment using a subcutaneous mode of administration a harringtonine salt or tautomeric form thereof, where the harringtonine is homoharringtonine or harringtonine having the following formula



where $n = 2$ or 3 ,

wherein said harringtonine is in a formulation in which

- (i) the pH of the formulation is between 5.5 and 8.5,
- (ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and
- (iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

Claim 33 (Currently Amended) The method of claim ~~34~~ 32, in which the acid which forms a salt of harringtonines is hydrochloric acid or tartaric acid.

Claim 34 (Currently Amended) The method of claim ~~34~~ 32, in which harringtonines are combined with another pharmaceutically acceptable agent in the same injection.

Claim 35 (Currently Amended) The method of claim ~~34~~ 32, in which the additional agent is a nucleoside.

Claim 36 (Currently Amended) The method of ~~therapy~~ of claim ~~34~~ 32, in which the subcutaneous mode of administration is performed by bolus injection at regular intervals.

Claim 37 (Currently Amended) The method of claim ~~34~~ 32, in which the subcutaneous mode of administration is performed by continuous subcutaneous infusion.

Claim 38 (Currently Amended) The method of claim ~~34~~ 32, wherein at least one additional antitumor agent is administered with the harringtonine.


Claim 39 (Currently Amended) The method of claim ~~34~~ 32, wherein the leukemia is selected from the group consisting of chronic myeloid leukemia, acute

myeloid leukemia, acute nonlymphocytic leukemia, acute myelocytic leukemia and myelodysplastic syndrome.

Claim 40 (Currently Amended) The method of claim ~~34~~ 32, wherein chronic myeloid leukemia is the leukemia to be treated.

Claim 41 (Canceled)

Claim 42 (Currently Amended) The method of claim ~~34~~ 32, where the harringtonine is a harringtonine salt having the following formula



where A⁻ is

a mineral anion selected from the group consisting of chloride, sulfate, nitrate, and perchlorate, or

an organic ion selected from the group consisting of tartarate, malate, lactate, and citrate, and p is 1 or 2.

Claim 43 (Currently Amended) The method of claim 35, in which the nucleoside is cytosine arabinoside.

Claim 44 (Currently Amended) The method of claim 36, in which the subcutaneous mode of administration is performed by bolus injection at one to four injections a day for at least one day.

Claim 45 (Previously Presented) The method of claim 36, in which the subcutaneous mode of administration is performed by bolus injection at one to four injections a day for 28 days.